FDA Still Feels Transvaginal Mesh Products Too Risky After Final Postmarketing Study
After reviewing the final postmarketing study on Coloplast transvaginal mesh, the FDA has determined the risks still outweigh the potential benefits.
After reviewing the final postmarketing study on Coloplast transvaginal mesh, the FDA has determined the risks still outweigh the potential benefits.
New postmarketing surveillance studies show Boston Scientific transvaginal mesh increase the risk of health complications for pelvic organ prolapse patients, without adding any additional effectiveness or safety over traditional surgical…
The FDA has banned the sale and distribution of transvaginal mesh products in the United States, saying they cannot guarantee the devices are safe or effective for women.
The FDA has announce new rules that reclassify transvaginal mesh products as high-risk medical devices and will require them to go through a more stringent approval process showing safety and…
Another group status conference has been ordered for all vaginal mesh lawsuits in an effort to reach a settlement that would avoid tens of thousands of trials.
A judge is pushing parties to settlement vaginal mesh lawsuits to avoid tens of thousands of cases going to trial.
Coloplast and plaintiffs continue to move toward a vaginal mesh settlement according to a federal judge.
Nearly 60,000 lawsuits involving vaginal mesh and bladder sling products are currently pending in federal MDLs.
The FDA has proposed reclassifying transvaginal mesh products as high-risk medical devices.
About 400 Coloplast vaginal mesh lawsuits have reportedly been settled for $16 million.